Holen Sie sich die Stockscreener-App
9.10
0.11%
0.010
Schlusskurs vom Vortag:
$9.09
Offen:
$9.25
24-Stunden-Volumen:
1,681
Relative Volume:
0.00
Marktkapitalisierung:
$6.95M
Einnahmen:
$202.00K
Nettoeinkommen (Verlust:
$-28.96M
KGV:
-15.17
EPS:
-0.6
Netto-Cashflow:
$-21.85M
1W Leistung:
+2.82%
1M Leistung:
+9,489%
6M Leistung:
+4,642%
1J Leistung:
+2,359%
1-Tages-Spanne:
$9.10
$9.25
1-Wochen-Bereich:
$8.8601
$9.585
52-Wochen-Spanne:
$0.0633
$14.93
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Vergleichen Sie AIM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
9.10 | 6.76M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.06 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.49 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.44 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.10 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.37 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
Omega Therapeutics (NASDAQ:OMGA) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Review - Defense World
AIM ImmunoTech Announces Recent Presentation on the - GlobeNewswire
AIM ImmunoTech (NYSE:AIM) Shares Gap Up – Here’s What Happened - Defense World
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements - The Manila Times
AIM ImmunoTech's Compliance Crossroads: Balancing Risk and Reward in a High-Stakes Gamble - AInvest
AIM ImmunoTech resumes trading on NYSE American By Investing.com - Investing.com India
AIM ImmunoTech resumes trading on NYSE American - Investing.com
AIM ImmunoTech Resumes Trading on NYSE American - The Manila Times
AIM ImmunoTech Inc. Common Stock Resumes Trading on NYSE American - Nasdaq
Aim Immunotech CEO Thomas Equels acquires $823 in common stock By Investing.com - Investing.com India
Aim Immunotech CEO Thomas Equels acquires $823 in common stock - Investing.com
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
Aim Immunotech CEO Thomas Equels acquires shares worth $896 By Investing.com - Investing.com Nigeria
Aim Immunotech CEO Thomas Equels acquires shares worth $896 - Investing.com Australia
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension - GlobeNewswire
AIM ImmunoTech Regains NYSE Compliance, Stock Reinstated - TipRanks
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® - The Manila Times
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, ... - Bluefield Daily Telegraph
New Patent Grant Extends Ampligen Manufacturing Protection for 18 Years: Major Win for Cancer and COVID Drug - Stock Titan
NYSE American Lifts AIM ImmunoTech Trading Ban After Stock Price Recovery - Stock Titan
AIM ImmunoTech Inc. Announces 1-for-100 Reverse Stock Split Effective June 12, 2025 - Nasdaq
Aim Immunotech Announces 1-For-100 Reverse Stock Split - MarketScreener
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split - GlobeNewswire
AIM ImmunoTech Sets Massive 1:100 Reverse Split to Save NYSE American Listing - Stock Titan
AIM ImmunoTech Reports Q1 2025 Financial Results - TipRanks
AIM ImmunoTech Announces the Presentation of Ampligen - GlobeNewswire
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists - Stock Titan
AIM ImmunoTech Announces Launch of CEO Corner Platform - Investegate
AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 - ACCESS Newswire
AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference - ACCESS Newswire
AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome - ACCESS Newswire
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19 - ACCESS Newswire
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - The Globe and Mail
AIM ImmunoTech Inc. Names Ellen Lintal as New Chief Financial Officer - marketscreener.com
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
AIM ImmunoTech appoints Chemerow as an Independent Director - MSN
Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock - Investing.com Canada
AIM ImmunoTech begins trading under new ticker AIMI - Investing.com Australia
AIM ImmunoTech begins trading under new ticker AIMI By Investing.com - Investing.com India
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - The Manila Times
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
AIM ImmunoTech Inc-Aktie (AIM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rodino Peter W III | COO, Secretary, Gen. Counsel |
Apr 04 '25 |
Buy |
0.09 |
500 |
44 |
401,762 |
| Equels Thomas K | CEO & President |
Mar 05 '25 |
Buy |
0.13 |
50,000 |
6,730 |
1,858,029 |
| Equels Thomas K | CEO & President |
Mar 04 '25 |
Buy |
0.12 |
44,000 |
5,060 |
1,808,029 |
| Equels Thomas K | CEO & President |
Mar 04 '25 |
Buy |
0.12 |
83,334 |
10,000 |
1,764,029 |
| Equels Thomas K | CEO & President |
Nov 21 '24 |
Buy |
0.21 |
20,000 |
4,240 |
1,657,968 |
| MITCHELL WILLIAM M | Director |
Dec 19 '24 |
Sale |
0.19 |
4,580 |
884 |
118,549 |
| Equels Thomas K | CEO & President |
Dec 18 '24 |
Buy |
0.21 |
22,727 |
4,682 |
1,680,695 |
| APPELROUTH STEWART | Director |
Dec 02 '24 |
Buy |
0.21 |
11,112 |
2,356 |
355,509 |
| Equels Thomas K | CEO & President |
Nov 20 '24 |
Buy |
0.20 |
85,000 |
16,915 |
1,637,968 |
| APPELROUTH STEWART | Director |
Nov 20 '24 |
Buy |
0.19 |
81,953 |
15,817 |
321,752 |
0.24%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):